Franklin Resources Inc. Increases Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Franklin Resources Inc. raised its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 7.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 29,981 shares of the specialty pharmaceutical company’s stock after purchasing an additional 2,121 shares during the period. Franklin Resources Inc.’s holdings in Supernus Pharmaceuticals were worth $987,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of SUPN. GAMMA Investing LLC boosted its position in shares of Supernus Pharmaceuticals by 97.1% during the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock valued at $25,000 after buying an additional 398 shares during the last quarter. Meeder Asset Management Inc. bought a new stake in shares of Supernus Pharmaceuticals in the second quarter worth approximately $47,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Supernus Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock valued at $61,000 after purchasing an additional 352 shares during the last quarter. nVerses Capital LLC bought a new position in Supernus Pharmaceuticals during the second quarter valued at approximately $72,000. Finally, Kennebec Savings Bank purchased a new stake in Supernus Pharmaceuticals in the third quarter worth approximately $103,000.

Insider Buying and Selling

In related news, Director Georges Gemayel sold 14,213 shares of the stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $36.62, for a total transaction of $520,480.06. Following the completion of the sale, the director now owns 13,315 shares in the company, valued at approximately $487,595.30. This trade represents a 51.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Jack A. Khattar sold 125,000 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.68, for a total value of $4,585,000.00. Following the completion of the transaction, the chief executive officer now directly owns 926,172 shares in the company, valued at approximately $33,971,988.96. This represents a 11.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 154,213 shares of company stock valued at $5,660,180. 9.30% of the stock is owned by corporate insiders.

Supernus Pharmaceuticals Price Performance

Shares of Supernus Pharmaceuticals stock opened at $37.18 on Friday. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $39.37. The company’s fifty day simple moving average is $35.88 and its 200-day simple moving average is $32.53. The stock has a market capitalization of $2.05 billion, a PE ratio of 34.75 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The business had revenue of $175.70 million during the quarter, compared to analysts’ expectations of $157.35 million. During the same quarter in the prior year, the business posted ($0.29) earnings per share. The business’s quarterly revenue was up 14.2% on a year-over-year basis. As a group, research analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on SUPN. Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.